Get past the hype and bias in sequencing vendor marketing materials, and get an unbiased, highly informed view from a highly qualified professional whose job it is to evaluate sequencing technologies for a world leading healthcare and research institution – the Mayo Clinic. Get a base- to high-level understanding of the sequencing process, to give […]
Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc. (PacBio) announced that they have mutually agreed to terminate their merger agreement. The merger was first proposed in November 2018 that Illumina would be acquiring PacBio at a fully diluted enterprise value of ~$1.2 billion. Now with the merger terminated, Illumina will have to pay a termination fee of $98 million to PacBio.
The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
In this open discussion webinar, DNA Genotek and Illumina discuss what’s trending in whole genome sequencing (WGS).
Illumina has revealed that it has acquired Edico Genome, with the intention of building on the solid foundation of DRAGEN, to deliver a more streamlines sample for customers.
Illumina’s new Bay Area campus boasts connectivity, collaboration, and innovation, but some are unsure whether it will be able to draw in the appeal from workers.
Illumina and Loxo Oncology have announced a global strategic partnership to develop a diagnostic tool that will work with Loxo’s larotrectinib and another of its experimental cancers drugs, across tumour types.
Comparison of Single Nucleotide Variants in Sequencing Data Produced by Illumina and Oxford Nanopore Technologies.
Come hear from David Grieg, Bioinformatician at Public Health England to learn more about the application of the MinION for the surveillance of Shiga toxin-producing Escherichia coli O157:H7.